Therapeutic Applications of Polymeric Materials

Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices

Volumn , Issue , 2017, Pages 1-19

  Cholkar, Kishore ^a   Acharya, Gayathri ^b   Trinh, Hoang M ^c   Singh, Gagandeep ^d  

^a Ingenus Pharmaceuticals RiconPharma LLC   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Diagnostic; Drug delivery; Engineering; Imaging; Implants; Micelles; Ocular; Polymerization; Tissue

Indexed keywords

EID: 85054277500     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-42978-8.00001-2     Document Type: Chapter

References (96)

1. Saravanabhavan S.S., Dharmalingam S. Fabrication of polysulphone/hydroxyapatite nanofiber composite implant and evaluation of their in vitro bioactivity and biocompatibility towards the post-surgical therapy of gastric cancer. Chem Eng J 2013, 234:380-388.
2. Liu S., Maheshwari R., Kiick K.L. Polymer-based therapeutics. Macromolecules 2009, 42(1):3-13.
3. Pandey S.K., Haldar C., Patel D.K., Maiti P. Biodegradable polymers for potential delivery systems for therapeutics. Adv Polym Sci 2013, 254:169-202.
4. Bachelder E.M., et al. Acetal-derivatized dextran: an acid-responsive biodegradable material for therapeutic applications. J Am Chem Soc 2008, 130(32):10494-10495.
5. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6(9):688-701.
6. Huang Y., et al. Synthesis and therapeutic applications of biocompatible or biodegradable hyperbranched polymers. Polym Chem 2015, 6:2794-2812.
7. Cholkar K., Gilger B.C., Mitra A.K. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm 2016, 498(1-2):326-334.
8. Toshinobu Higashimura M.S. Living polymerization and selective dimerization: two extremes of the polymer synthesis by cationic polymerization. Adv Polym Sci 2005, 62:49-94.
9. Yoshihiko Ito T.M., Suginome M. Structural modification of living polymers: synthesis of helical block copolymers from a single monomer via palladium-mediated aromatizing polymerization of 1,2-diisocyanobenzenes. Macromolecules 2000, 33(11):4034-4038.
10. Liechty W.B., et al. Polymers for drug delivery systems. Annu Rev Chem Biomol Eng 2010, 1:149-173.
11. Cascone M.G., Sim B., Downes S. Blends of synthetic and natural polymers as drug delivery systems for growth hormone. Biomaterials 1995, 16(7):569-574.
12. Park T.G., Langer R.S. Controlled drug delivery using polymer/pluronic blends 1994, Google patents, (USA).
13. Marks J.A., et al. Pairwise polymer blends for oral drug delivery. J Pharm Sci 2014, 103(9):2871-2883.
14. Munj H.R., et al. Biocompatible electrospun polymer blends for biomedical applications. J Biomed Mater Res B Appl Biomater 2014, 102(7):1517-1527.
15. Tipduangta P., et al. Electrospun polymer blend nanofibers for tunable drug delivery: the role of transformative phase separation on controlling the release rate. Mol Pharm 2016, 13(1):25-39.
16. Tian-Bin Ren Y.F., Zhang Z.-H., Li L., Li Y.-Y. Shell-sheddable micelles based on star-shaped poly(ε-caprolactone)-SS-poly(ethyl glycol) copolymer for intracellular drug release. Soft Matter 2011, 7:2329-2331.
17. Shuai X., et al. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Control Release 2004, 98(3):415-426.
18. Ikada Y., Tsuji H. Biodegradable polyesters for medical and ecological applications. Macromol Rapid Commun 2000, 21(3):117-132.
19. Binauld S., Stenzel M.H. Acid-degradable polymers for drug delivery: a decade of innovation. Chem Commun 2013, 49:2082-2102.
20. Boomer J.A., Inerowicz H.D., Zhang Z.-Y., Bergstrand N., Edwards K., Kim J.-M., Thompson D.H. Acid-triggered release from sterically stabilized fusogenic liposomes via a hydrolytic dePEGylation strategy. Langmuir 2003, 19(16):6408-6415.
21. Takae S., et al. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J Am Chem Soc 2008, 130(18):6001-6009.
22. Saito G., Swanson J.A., Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55(2):199-215.
23. Jin H., et al. Biocompatible or biodegradable hyperbranched polymers: from self-assembly to cytomimetic applications. Chem Soc Rev 2012, 41(18):5986-5997.
24. Wang D., et al. Bioapplications of hyperbranched polymers. Chem Soc Rev 2015, 44(12):4023-4071.
25. Calderon M., et al. Dendritic polyglycerols for biomedical applications. Adv Mater 2010, 22(2):190-218.
26. Qi Zhu F.Q., Zhu B., Zhu X. Hyperbranched polymers for bioimaging. R Chem Soc Adv 2013, 3:2071-2083.
27. Yuanyuan Zhuang Q.Z., Tu C., Wang D., Wu J., Xia Y., Tong G., He L., Zhu B., Yan D., Zhu X. Protein resistant properties of polymers with different branched architecture on a gold surface. J Mater Chem 2012, 22:23852-23860.
28. Zhuang Y., et al. Facile fabrication of redox-responsive thiol-containing drug delivery system via RAFT polymerization. Biomacromolecules 2014, 15(4):1408-1418.
29. Chen C., Liu G., Liu X., Pang S., Zhu C., Lv L., Ji J. Photo-responsive, biocompatible polymeric micelles self-assembled from hyperbranched polyphosphate-based polymers. Polym Chem 2011, 2:1389-1397.
30. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83(5):761-769.
31. Davis F.F. Peptide and protein pegylation. Adv Drug Deliv Rev 2002, 54(4):457-458.
32. Mitra A.K., Pentablock polymers 2010, Google patents, (USA).
33. Cholkar K., Gilger B.C., Mitra A.K. Corrigendum to "topical delivery of aqueous micellar resolvin E1 analog (RX-10045)". Int J Pharm 2016, 509(1-2):528. Int. J. Pharm. 498 (2016) 326-334.
34. Cholkar K., Gilger B.C., Mitra A.K. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl Vis Sci Technol 2015, 4(3):1.
35. Cholkar K., et al. Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery. AAPS PharmSciTech 2015, 16(3):610-622.
36. Cholkar K., et al. Optimization of dexamethasone mixed nanomicellar formulation. AAPS PharmSciTech 2014, 15(6):1454-1467.
37. Vadlapudi A.D., et al. Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility. J Ocul Pharmacol Ther 2014, 30(1):49-58.
38. Earla R., et al. Bioanalytical method validation of rapamycin in ocular matrix by QTRAP LC-MS/MS: application to rabbit anterior tissue distribution by topical administration of rapamycin nanomicellar formulation. J Chromatogr B Anal Technol Biomed Life Sci 2012, 908:76-86.
39. Earla R., et al. Development and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids - quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2010, 52(4):525-533.
40. Ito M. In vitro properties of a chitosan-bonded hydroxyapatite bone-filling paste. Biomaterials 1991, 12(1):41-45.
41. Higashi S., et al. Polymer-hydroxyapatite composites for biodegradable bone fillers. Biomaterials 1986, 7(3):183-187.
42. Ge Z., et al. Hydroxyapatite-chitin materials as potential tissue engineered bone substitutes. Biomaterials 2004, 25(6):1049-1058.
43. Tokura S., Tamura H. O-carboxymethyl-chitin concentration in granulocytes during bone repair. Biomacromolecules 2001, 2(2):417-421.
44. Farzadi A., Solati-Hashjin M., Bakhshi F., Aminian A. Synthesis and characterization of hydroxyapatite/β-tricalcium phosphate nanocomposites using microwave irradiation. Ceram Int 2011, 37(1):65-71.
45. Murugan R., Ramakrishna S. Bioresorbable composite bone paste using polysaccharide based nano hydroxyapatite. Biomaterials 2004, 25(17):3829-3835.
46. Chen F., Wang Z.-C., Lin C.-J. Preparation and characterization of nanosized hydroxyapatite particles and hydroxyapatite/chitosan nanocomposite for use in biomedical materials. Mater Lett 2002, 57:858-861.
47. Sudheesh Kumar P.T., Srinivasan S., Lakshmanan V.-K., Tamura H., Nair S.V., Jayakumar R. β-Chitin hydrogel/nano hydroxyapatite composite scaffolds for tissue engineering applications. Carbohydr Polym 2011, 85(3):584-591.
48. Kumar P.T., et al. Synthesis, characterization and cytocompatibility studies of alpha-chitin hydrogel/nano hydroxyapatite composite scaffolds. Int J Biol Macromol 2011, 49(1):20-31.
49. Ulery B.D., Nair L.S., Laurencin C.T. Biomedical applications of biodegradable polymers. J Polym Sci B Polym Phys 2011, 49(12):832-864.
50. Maitz M.F. Applications of synthetic polymers in clinical medicine. Biosurface Biotribol 2015, 1(3):161-176.
51. Wang Y.-J., Larsson M., Huanga W.-T., Chiouc S.-H., Nichollsd S.J., Chaoe J.-I., Liu D.-M. The use of polymer-based nanoparticles and nanostructured materials in treatment and diagnosis of cardiovascular diseases: recent advances and emerging designs. Prog Polym Sci 2016, 57:153-178.
52. 3+-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-2-hydroxypropyl-beta-cyclodex trin/pluronic polyrotaxane as a long circulating high relaxivity MRI contrast agent. ACS Appl Mater Interfaces 2015, 7(40):22272-22276.
53. Rudovsky J., et al. PAMAM dendrimeric conjugates with a Gd-DOTA phosphinate derivative and their adducts with polyaminoacids: the interplay of global motion, internal rotation, and fast water exchange. Bioconjug Chem 2006, 17(4):975-987.
54. Xu R., et al. Synthesis and evaluation of nanoglobule-cystamine-(Gd-DO3A), a biodegradable nanosized magnetic resonance contrast agent for dynamic contrast-enhanced magnetic resonance urography. Int J Nanomed 2010, 5:707-713.
55. Laus S., et al. Rotational dynamics account for pH-dependent relaxivities of PAMAM dendrimeric, Gd-based potential MRI contrast agents. Chemistry 2005, 11(10):3064-3076.
56. Ye Z., et al. Polydisulfide manganese(II) complexes as non-gadolinium biodegradable macromolecular MRI contrast agents. J Magn Reson Imaging 2012, 35(3):737-744.
57. Rowe M.D., et al. Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. Langmuir 2009, 25(16):9487-9499.
58. Cheng K.T., Lu Z.R., Kaneshiro T. Gd-DTPA l-Cystine bispropyl amide copolymers. Molecular Imaging and Contrast Agent Database (MICAD) 2004, Bethesda (MD).
59. Chen K.J., et al. A small MRI contrast agent library of gadolinium(III)-encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity. Biomaterials 2011, 32(8):2160-2165.
60. Hu J., et al. Drug-loaded and superparamagnetic iron oxide nanoparticle surface-embedded amphiphilic block copolymer micelles for integrated chemotherapeutic drug delivery and MR imaging. Langmuir 2012, 28(4):2073-2082.
61. Li X., et al. Amphiphilic multiarm star block copolymer-based multifunctional unimolecular micelles for cancer targeted drug delivery and MR imaging. Biomaterials 2011, 32(27):6595-6605.
62. Lu Z.R., et al. Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents. Int J Nanomed 2006, 1(1):31-40.
63. Mohs A.M., Lu Z.R. Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliv 2007, 4(2):149-164.
64. Zong Y., et al. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice. Magn Reson Med 2005, 53(4):835-842.
65. Chowdhury S.R., et al. Simultaneous evaluation of substrate-dependent oxygen consumption rates and mitochondrial membrane potential by TMRM and safranin in cortical mitochondria. Biosci Rep 2016, 36(1):e00286.
66. Graef F., Gordon S., Lehr C.M. Anti-infectives in drug delivery-overcoming the gram-negative bacterial cell envelope. Curr Top Microbiol Immunol 2016, 398:475-496.
67. Olson E.S., et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci USA 2010, 107(9):4311-4316.
68. Nguyen Q.T., et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA 2010, 107(9):4317-4322.
69. Ametamey S.M., Honer M., Schubiger P.A. Molecular imaging with PET. Chem Rev 2008, 108(5):1501-1516.
70. Chakravarty R., Hong H., Cai W. Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm 2014, 11(11):3777-3797.
71. Lammers T., et al. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 2010, 7(6):1899-1912.
72. 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J Nucl Med 2008, 49(1):103-111.
73. 64Cu-labeled hAb47 and hAb131 antibodies. J Nucl Med 2013, 54(7):1094-1100.
74. 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 2011, 102(1):117-121.
75. Jensen A.I., et al. Positron emission tomography based analysis of long-circulating cross-linked triblock polymeric micelles in a U87MG mouse xenograft model and comparison of DOTA and CB-TE2A as chelators of copper-64. Biomacromolecules 2014, 15(5):1625-1633.
76. Xiao Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33(11):3071-3082.
77. Mariani G., et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging 2010, 37(10):1959-1985.
78. Chakravarty R., Hong H., Cai W. Image-guided drug delivery with single-photon emission computed tomography: a review of literature. Curr Drug Targets 2015, 16(6):592-609.
79. Brandon D., et al. The role of single-photon emission computed tomography and SPECT/computed tomography in oncologic imaging. Semin Oncol 2011, 38(1):87-108.
80. Patil V., et al. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates. Eur J Nucl Med Mol Imaging 2012, 39(5):824-839.
81. 111In-labeled polymeric micelles. Int J Nanomed 2013, 8:1385-1391.
82. Khaw B.A., et al. Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts: targeted polymer drug conjugates for cancer diagnosis and therapy. Eur J Nucl Med Mol Imaging 2014, 41(8):1603-1616.
83. Wang Z., et al. The effect of thick fibers and large pores of electrospun poly(epsilon-caprolactone) vascular grafts on macrophage polarization and arterial regeneration. Biomaterials 2014, 35(22):5700-5710.
84. Li P., et al. Applying electrospun gelatin/poly(lactic acid-co-glycolic acid) bilayered nanofibers to fabrication of meniscal tissue engineering scaffold. J Nanosci Nanotechnol 2016, 16(5):4718-4726.
85. Sandri M., et al. Fabrication and pilot in vivo study of a collagen-BDDGE-elastin core-shell scaffold for tendon regeneration. Front Bioeng Biotechnol 2016, 4:52.
86. Forget J., et al. Differentiation of human mesenchymal stem cells toward quality cartilage using fibrinogen-based nanofibers. Macromol Biosci 2016.
87. Gugutkov D., et al. Electrospun fibrinogen-PLA nanofibres for vascular tissue engineering. J Tissue Eng Regen Med 2016, 10.1002/term.2172.
88. Singh B.N., et al. Carboxymethyl cellulose enables silk fibroin nanofibrous scaffold with enhanced biomimetic potential for bone tissue engineering application. Carbohydr Polym 2016, 151:335-347.
89. Singh Y.P., Bhardwaj N., Mandal B.B. Potential of agarose/silk fibroin blended hydrogel for in vitro cartilage tissue engineering. ACS Appl Mater Interfaces 2016.
90. Park Y.R., et al. Three-dimensional electrospun silk-fibroin nanofiber for skin tissue engineering. Int J Biol Macromol 93(Pt B), December 2016, 1567-1574.
91. Dhand C., et al. Bio-inspired in situ crosslinking and mineralization of electrospun collagen scaffolds for bone tissue engineering. Biomaterials October 2016, 104:323-338.
92. Huang L., et al. Morphological study of dynamic culture of thermosensitive collagen hydrogel in constructing tissue engineering complex. Bioengineered 2016, 7(4):266-273.
93. Pinnagoda K., et al. Engineered acellular collagen scaffold for endogenous cell guidance, a novel approach in urethral regeneration. Acta Biomater 2016.
94. Lih E., et al. Biomimetic porous PLGA scaffolds incorporating decellularized extracellular matrix for kidney tissue regeneration. ACS Appl Mater Interfaces August 24, 2016, 8(33):21145-21154.
95. Dai Y., et al. Cell-free HA-MA/PLGA scaffolds with radially oriented pores for in situ inductive regeneration of full thickness cartilage defects. Macromol Biosci November 2016, 16(11):1632-1642.
96. Yan W., et al. In vitro investigation of nanohydroxyapatite/poly(l-lactic acid) spindle composites used for bone tissue engineering. J Mater Sci Mater Med 2016, 27(8):130.